Your browser is no longer supported. Please, upgrade your browser.
BTAI [NASD]
BioXcel Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.78 Insider Own0.20% Shs Outstand24.39M Perf Week3.11%
Market Cap776.36M Forward P/E- EPS next Y-3.39 Insider Trans-71.49% Shs Float14.67M Perf Month-10.09%
Income-82.20M PEG- EPS next Q-0.94 Inst Own51.90% Short Float22.97% Perf Quarter-48.15%
Sales- P/S- EPS this Y-87.20% Inst Trans-5.91% Short Ratio7.20 Perf Half Y-44.38%
Book/sh8.47 P/B3.72 EPS next Y23.80% ROA-53.40% Target Price- Perf Year-31.36%
Cash/sh8.64 P/C3.64 EPS next 5Y- ROE-59.40% 52W Range28.00 - 71.50 Perf YTD-31.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.99% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low12.39% ATR1.96
Employees50 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)39.73 Volatility9.21% 6.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-88.80% Profit Margin- Rel Volume1.03 Prev Close30.40
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume467.81K Price31.47
Recom1.60 SMA20-4.98% SMA50-17.33% SMA200-31.31% Volume480,290 Change3.52%
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Oct-30-20Initiated Goldman Buy $60
Sep-02-20Initiated Jefferies Buy $82
Aug-17-20Reiterated H.C. Wainwright Buy $200 → $175
Jul-08-20Reiterated H.C. Wainwright Buy $95 → $120
Jun-04-20Initiated Guggenheim Buy $101
Apr-01-20Initiated BofA/Merrill Buy $45
Feb-26-20Reiterated H.C. Wainwright Buy $30 → $95
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-12-19Initiated SunTrust Buy $24
May-12-21 08:20AM  
May-11-21 07:00AM  
May-10-21 07:00AM  
06:45AM  
May-04-21 07:00AM  
May-03-21 07:00AM  
Apr-29-21 07:00AM  
Apr-26-21 07:00AM  
Apr-16-21 12:16PM  
Apr-15-21 08:00AM  
Apr-01-21 02:54PM  
06:26AM  
Mar-31-21 04:01PM  
Mar-16-21 06:07AM  
Mar-15-21 07:00AM  
Mar-11-21 08:19AM  
07:15AM  
07:00AM  
05:30AM  
Mar-04-21 07:00AM  
Mar-03-21 09:49AM  
07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 11:46AM  
07:00AM  
05:30AM  
Feb-23-21 07:00AM  
Feb-17-21 10:00AM  
12:27AM  
Feb-12-21 07:00AM  
Feb-04-21 07:00AM  
Feb-01-21 04:54PM  
Jan-07-21 05:45AM  
Jan-05-21 07:00AM  
Dec-26-20 05:30PM  
Dec-17-20 07:00AM  
Dec-13-20 09:12AM  
Dec-12-20 10:42AM  
Dec-07-20 07:00AM  
Nov-16-20 09:06AM  
Nov-13-20 07:00AM  
Nov-12-20 07:00AM  
06:45AM  
Nov-11-20 07:00AM  
Nov-09-20 08:05AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Sep-25-20 11:25AM  
Sep-09-20 07:00AM  
Aug-21-20 10:20AM  
Aug-17-20 06:02AM  
Aug-14-20 12:34PM  
07:00AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Jul-28-20 08:20PM  
Jul-27-20 04:21PM  
Jul-22-20 05:45AM  
Jul-20-20 04:33PM  
04:27PM  
11:44AM  
07:00AM  
Jul-09-20 07:00AM  
Jul-07-20 07:00AM  
Jul-05-20 09:21PM  
Jun-23-20 07:00AM  
Jun-17-20 09:43AM  
Jun-16-20 07:00AM  
Jun-15-20 04:05PM  
Jun-11-20 07:00AM  
Jun-04-20 09:42AM  
May-28-20 07:00AM  
May-15-20 05:45AM  
May-14-20 07:00AM  
May-12-20 10:31PM  
07:00AM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 07:00AM  
Apr-28-20 07:00AM  
Apr-24-20 07:21AM  
Mar-24-20 04:23PM  
Mar-19-20 07:15AM  
Mar-17-20 10:55AM  
Mar-09-20 07:00AM  
06:00AM  
Mar-02-20 07:00AM  
Feb-28-20 08:20AM  
Feb-26-20 07:00AM  
Feb-20-20 07:30AM  
Feb-19-20 04:54PM  
07:21AM  
Feb-18-20 07:00AM  
Feb-07-20 07:00AM  
Feb-06-20 07:47AM  
Feb-05-20 07:00AM  
Jan-28-20 06:13PM  
Jan-25-20 09:28AM  
Jan-10-20 06:45AM  
Jan-07-20 07:00AM  
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yocca FrankChief Scientific OfficerMar 15Sale48.5015,000727,57358,397Mar 17 05:00 PM
O'Neill VincentChief Medical OfficerFeb 17Option Exercise4.6525,000116,15025,000Feb 19 07:35 PM
O'Neill VincentChief Medical OfficerFeb 17Sale55.5825,0001,389,4590Feb 19 07:35 PM
Yocca FrankChief Scientific OfficerFeb 16Sale57.6815,000865,15373,397Feb 18 04:56 PM
Steinhart Richard IChief Financial OfficerFeb 01Option Exercise5.553,75020,8125,250Feb 03 04:15 PM
Steinhart Richard IChief Financial OfficerFeb 01Sale48.153,750180,5621,500Feb 03 04:15 PM
Yocca FrankChief Scientific OfficerJan 25Option Exercise0.4115,0006,150103,397Jan 27 04:25 PM
Yocca FrankChief Scientific OfficerJan 25Sale48.3915,000725,81488,397Jan 27 04:25 PM
O'Neill VincentChief Medical OfficerJan 19Option Exercise0.4125,00010,25025,000Jan 21 04:15 PM
O'Neill VincentChief Medical OfficerJan 19Sale49.4725,0001,236,7190Jan 21 04:15 PM
O'Neill VincentChief Medical OfficerDec 28Option Exercise0.4125,00010,25025,000Dec 30 04:15 PM
O'Neill VincentChief Medical OfficerDec 28Sale51.4525,0001,286,1570Dec 30 04:15 PM